November6 , 2026

    China grants zero duty to Indian pharma as US blocks imports with 100% tariff

    Related

    Deendayal Port Rewards Employees with Diwali Vouchers Following Record Cargo Performance

    Deendayal Port Authority (DPA) has achieved historic milestones in...

    VOC Port Records Five Years of Steady Cargo Growth, Reaches 43.3 MMT in FY26

    V.O. Chidambaranar Port Authority (VOC Port) has recorded consistent...

    Paradip Port Records 16.89% Growth in Thermal Coal Handling

    Paradip Port Authority has registered an impressive 16.89% year-on-year...

    JNPA Records Strong Growth in Cargo Traffic in October 2026

    Jawaharlal Nehru Port Authority (JNPA) recorded an impressive performance...

    Share

    In a major development, China has slashed the 30 percent import duty on Indian pharmaceutical products to zero. This landmark step will allow Indian drug manufacturers to export medicines to China without paying any customs duty. Experts say this decision could boost Indian pharma exports by billions of dollars in the coming years.

    Timing important as US raises tariffs

    The announcement comes just after US President Donald Trump imposed a 100 percent tariff on pharma imports, a move that could hurt India’s large drug-exporting industry. With the US market becoming costlier, China’s decision offers Indian companies an alternative market with strong demand for affordable medicines.

    Why it matters for India

    India is known as the ‘pharmacy of the world,’ supplying affordable generic drugs and vaccines across the globe. The Chinese market, with its huge population and growing healthcare needs, has long been difficult for Indian exporters due to high duties. Now, with a zero percent duty, Indian companies will have a level playing field and better access to one of the world’s largest healthcare markets.

    Experts see big opportunity

    Trade analysts believe this move will help balance India-China trade relations, which are often tilted in Beijing’s favour. Pharma industry leaders also expect this change to create thousands of jobs in India, boost revenues, and strengthen India’s position in global healthcare supply chains.